Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 15, 2026.

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis

You Li, Xin Wang, Dianna M Blau and 97 more

The Lancet · 2022 · Review · CC BY

doi:10.1016/s0140-6736(22)00478-0

Abstract

Background. Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory infection in young children. We previously estimated that in 2015, 33·1 million episodes of RSV-associated acute lower respiratory infection occurred in children aged 0–60 months, resulting in a total of 118 200 deaths worldwide. Since then, several community surveillance studies have been done to obtain a more precise estimation of RSV associated community deaths. We aimed to update RSV-associated acute lower respiratory infection morbidity and mortality at global, regional, and national levels in children aged 0–60 months for 2019, with focus on overall mortality and narrower infant age groups that are targeted by RSV prophylactics in development.

Methods. In this systematic analysis, we expanded our global RSV disease burden dataset by obtaining new data from an updated search for papers published between Jan 1, 2017, and Dec 31, 2020, from MEDLINE, Embase, Global Health, CINAHL, Web of Science, LILACS, OpenGrey, CNKI, Wanfang, and ChongqingVIP. We also included unpublished data from RSV GEN collaborators. Eligible studies reported data for children aged 0–60 months with RSV as primary infection with acute lower respiratory infection in community settings, or acute lower respiratory infection necessitating hospital admission; reported data for at least 12 consecutive months, except for in-hospital case fatality ratio (CFR) or for where RSV seasonality is well-defined; and reported incidence rate, hospital admission rate, RSV positive proportion in acute lower respiratory infection hospital admission, or in-hospital CFR. Studies were excluded if case definition was not clearly defined or not consistently applied, RSV infection was not laboratory confirmed or based on serology alone, or if the report included fewer than 50 cases of acute lower respiratory infection. We applied a generalised linear mixed-effects model (GLMM) to estimate RSV-associated acute lower respiratory infection incidence, hospital admission, and in-hospital mortality both globally and regionally (by country development status and by World Bank Income Classification) in 2019. We estimated country-level RSV-associated acute lower respiratory infection incidence through a risk-factor based model. We developed new models (through GLMM) that incorporated the latest RSV community mortality data for estimating overall RSV mortality. This review was registered in PROSPERO (CRD42021252400).

Findings. In addition to 317 studies included in our previous review, we identified and included 113 new eligible studies and unpublished data from 51 studies, for a total of 481 studies. We estimated that globally in 2019, there were 33·0 million RSV-associated acute lower respiratory infection episodes (uncertainty range [UR] 25·4–44·6 million), 3·6 million RSV-associated acute lower respiratory infection hospital admissions (2·9–4·6 million), 26 300 RSV-associated acute lower respiratory infection in-hospital deaths (15 100–49 100), and 101 400 RSV-attributable overall deaths (84 500–125 200) in children aged 0–60 months. In infants aged 0–6 months, we estimated that there were 6·6 million RSV-associated acute lower respiratory infection episodes (4·6–9·7 million), 1·4 million RSV-associated acute lower respiratory infection hospital admissions (1·0–2·0 million), 13 300 RSV-associated acute lower respiratory infection inhospital deaths (6800–28 100), and 45700 RSV-attributable overall deaths (38 400–55 900). 2·0% of deaths in children aged 0–60 months (UR 1·6–2·4) and 3·6% of deaths in children aged 28 days to 6 months (3·0–4·4) were attributable to RSV. More than 95% of RSV-associated acute lower respiratory infection episodes and more than 97% of RSV-attributable deaths across all age bands were in low-income and middle-income countries (LMICs).

Interpretation. RSV contributes substantially to morbidity and mortality burden globally in children aged 0–60 months, especially during the first 6 months of life and in LMICs. We highlight the striking overall mortality burden of RSV disease worldwide, with one in every 50 deaths in children aged 0–60 months and one in every 28 deaths in children aged 28 days to 6 months attributable to RSV. For every RSV-associated acute lower respiratory infection in-hospital death, we estimate approximately three more deaths attributable to RSV in the community. RSV passive immunisation programmes targeting protection during the first 6 months of life could have a substantial effect on reducing RSV disease burden, although more data are needed to understand the implications of the potential age-shifts in peak RSV burden to older age when these are implemented.

Funding. EU Innovative Medicines Initiative Respiratory Syncytial Virus Consortium in Europe (RESCEU).

References 34

  1. 1.
    Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study · 2019
    No notice
  2. 2.

    Bénet T, Sánchez Picot V, Messaoudi M, et al. Microorganisms associated with pneumonia in children <5 years of age in developing and emerging countries: the GABRIEL pneumonia multicenter, prospective, case-control study. Clin Infect Dis. 2017;65:604-12.

    Not in our library10.1093/cid/cix378

  3. 3.
    Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study · 2017
    No notice
  4. 4.

    Srikantiah P, Vora P, Klugman KP. Assessing the full burden of respiratory syncytial virus in young infants in low- and middleincome countries: the importance of community mortality studies. Clin Infect Dis. 2021;73(suppl 3):S177-79.

    Not in our library10.1093/cid/ciab486

  5. 5.
    Initial findings from a novel population-based child mortality surveillance approach: a descriptive study · 2020
    No notice
  6. 6.

    RSV Vaccine and mAb Snapshot. 2021.

    Not in our library

  7. 7.

    Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383:415-25.

    Not in our library10.1056/nejmoa1913556

  8. 8.

    Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386:837-46.

    Not in our library10.1056/nejmoa2110275

  9. 9.
    Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study · 2021
    No notice
  10. 10.

    Wang X, Li Y, Deloria-Knoll M, et al. Global burden of acute lower respiratory infection associated with human parainfluenza virus in children younger than 5 years for 2018: a systematic review and meta-analysis. Lancet Glob Health. 2021;9:e1077-87.

    Not in our library10.1016/s2214-109x(21)00218-7

  11. 11.
    Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study · 2020
    No notice
  12. 12.

    World population prospects 2019. 2019.

    Not in our library

  13. 13.

    Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med. 2000;19:3417-32.

    Not in our library10.1002/1097-0258(20001230)19:24<3417::aid-sim614>3.0.co;2-l

  14. 14.
    Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis · 2019
    No notice
  15. 15.
    Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 · 2018
    No notice
  16. 16.

    Blau DM, Baillie VL, Els T, et al. Deaths attributed to respiratory syncytial virus in young children in high-mortality rate settings: report from child health and mortality prevention surveillance (CHAMPS). Clin Infect Dis. 2021;73(suppl 3):S218-28.

    Not in our library10.1093/cid/ciab509

  17. 17.

    Caballero MT, Bianchi AM, Grigaites SD, et al. Community mortality due to respiratory syncytial virus in Argentina: population-based surveillance study. Clin Infect Dis. 2021;73(suppl 3):S210-17.

    Not in our library10.1093/cid/ciab497

  18. 18.

    Kazi AM, Aguolu OG, Mughis W, et al. Respiratory syncytial virus-associated mortality among young infants in Karachi, Pakistan: a prospective postmortem surveillance study. Clin Infect Dis. 2021;73(suppl 3):S203-09.

    Not in our library10.1093/cid/ciab488

  19. 19.

    Murphy C, MacLeod WB, Forman LS, et al. Risk factors for respiratory syncytial virus-associated community deaths in Zambian infants. Clin Infect Dis. 2021;73(suppl 3):S187-92.

    Not in our library10.1093/cid/ciab453

  20. 20.

    Satav A, Crow R, Potdar V, et al. The burden of respiratory syncytial virus in children under 2 years of age in a rural community in Maharashtra, India. Clin Infect Dis. 2021;73(suppl 3):S238-47.

    Not in our library10.1093/cid/ciab508

  21. 21.

    Li Y, Johnson EK, Shi T, et al. National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study. Lancet Respir Med. 2021;9:175-85.

    Not in our library10.1016/s2213-2600(20)30322-2

  22. 22.

    Wang X, Li Y, Mei X, Bushe E, Campbell H, Nair H. Global hospital admissions and in-hospital mortality associated with all-cause and virus-specific acute lower respiratory infections in children and adolescents aged 5-19 years between 1995 and 2019: a systematic review and modelling study. BMJ Glob Health. 2021;6:e006014.

    Not in our library10.1136/bmjgh-2021-006014

  23. 23.

    Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010;29:3046-67.

    Not in our library10.1002/sim.4040

  24. 24.

    Menendez C, Castillo P, Martínez MJ, et al. Validity of a minimally invasive autopsy for cause of death determination in stillborn babies and neonates in Mozambique: an observational study. PLoS Med. 2017;14:e1002318.

    Not in our library10.1371/journal.pmed.1002318

  25. 25.

    Mazur NI, Löwensteyn YN, Willemsen JE, et al. Global respiratory syncytial virus-related infant community deaths. Clin Infect Dis. 2021;73(suppl 3):S229-37.

    Not in our library10.1093/cid/ciab528

  26. 26.

    Simões EAF, Dani V, Potdar V, et al. Mortality from respiratory syncytial virus in children under 2 years of age: a prospective community cohort study in rural Maharashtra, India. Clin Infect Dis. 2021;73(suppl 3):S193-202.

    Not in our library10.1093/cid/ciab481

  27. 27.

    Saha S, Santosham M, Hussain M, Black RE, Saha SK. Rotavirus vaccine will improve child survival by more than just preventing diarrhea: evidence from Bangladesh. Am J Trop Med Hyg. 2018;98:360-63.

    Not in our library10.4269/ajtmh.17-0586

  28. 28.
    Association between Respiratory Syncytial Virus Activity and Pneumococcal Disease in Infants: A Time Series Analysis of US Hospitalization Data · 2015
    No notice
  29. 29.

    Li Y, Peterson ME, Campbell H, Nair H. Association of seasonal viral acute respiratory infection with pneumococcal disease: a systematic review of population-based studies. BMJ Open. 2018;8:e019743.

    Not in our library10.1136/bmjopen-2017-019743

  30. 30.

    Danino D, Ben-Shimol S, Van Der Beek BA, et al. Decline in pneumococcal disease in young children during the COVID-19 pandemic in Israel associated with suppression of seasonal respiratory viruses, despite persistent pneumococcal carriage: a prospective cohort Study. Clin Infect Dis. 2021.

    Not in our library10.1093/cid/ciab1014

  31. 31.

    Li Y, Campbell H, Nair H, Investigators R. Unveiling the risk period for death after respiratory syncytial virus illness in young children using a self-controlled case series design. J Infect Dis. 2020;222(suppl 7):S634-39.

    Not in our library10.1093/infdis/jiaa309

  32. 32.

    Fourgeaud J, Toubiana J, Chappuy H, et al. Impact of public health measures on the post-COVID-19 respiratory syncytial virus epidemics in France. Eur J Clin Microbiol Infect Dis. 2021;40:2389-95.

    Not in our library10.1007/s10096-021-04323-1

  33. 33.
    Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter? · 2021
    Corrected
  34. 34.

    Foley DA, Phuong LK, Peplinski J, et al. Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia. Arch Dis Child. 2022;107:e7.

    Not in our library10.1136/archdischild-2021-322507

Cited by papers we hold 4

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.